×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Liver Cancer

Jason M. Broderick
Opdivo (nivolumab) was granted a priority review designation by the Food and Drug Administration (FDA) to treat some patients with liver cancer.
Jason M. Broderick
The Food and Drug Administration (FDA) has approved Stivarga as a second-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who have previously received Nexavar.
Debu Tripathy, MD

Understanding liver cancer is a crucial step toward the prevention of this rare condition.

AIMEE SWARTZ
Liver cancer diagnoses and mortality have been rising, but new treatments are designed to help reverse the trend.
Jason M. Broderick
A recent phase 3 trial showed that treatment with Lenvima is noninferior to standard treatment for patients with unresectable liver cancer.
 
 
Jason M. Broderick
Stivarga was granted a priority review by the FDA to treat certain patients with liver cancer in the second line setting. 
Laura Panjwani
Stivarga is being considered by the FDA for approval for second-line liver cancer treatment, renewing hope in the field. 
Virginia Powers, PhD
After doing well in a phase 3 trial, Stivarga showed the potential to shift the treatment paradigm for previously treated liver cancer.
Greg Kennelty
Michael Choti talks about what kind of advances can be expected in treating liver cancer, including PD-1 inhibitors and neoadjuvant treatment.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable